arrow
F

Filippo Pederzoli

Weill Cornell Medicine
H指数:33
被引数:3,104

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Circulating cell-free methylated DNA immunoprecipitation sequencing (cfMeDIP-seq) in oncology: from technological advances to clinical applications

循环游离甲基化DNA免疫沉淀测序(cfMeDIP-seq)在肿瘤学中的应用:从技术进步到临床应用

2026-05-250
OAAI
Lipidomic profiling in metastatic prostate cancer captures tumor metabolic rewiring and its modulation by androgen receptor–targeting therapy

脂质组学分析在转移性前列腺癌中捕获了肿瘤代谢重编程及其通过雄激素受体靶向治疗的调节

2026-03-130
OAAI
HER2 and urothelial carcinoma: current understanding and future directions

HER2与尿路上皮癌:当前认知与未来方向

2025-08-150
PRE
Stool Microbiome Signature Associated with Response to Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Cancer
2024-05-011
OA
Distinct mesenchymal cell states mediate prostate cancer progression
2024-01-088
OAAI
Concomitant vs Staged Therapeutic Inguinal Lymphadenectomy in Clinically Node Positive Penile Squamous Cell Carcinoma: Does It Make a Difference?
2023-03-011
PRE
Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer
2023-02-035
OAAI
Perioperative and oncologic outcomes of open radical nephrectomy and inferior vena cava thrombectomy with liver mobilization and Pringle maneuver for Mayo III level tumor thrombus: single institution experience
2022-02-014
PRE
A global approach to improving penile cancer care (Jan, 2022)
2022-01-183
OAAI
A global approach to improving penile cancer care
2021-12-2241
OAAI
Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study
2021-12-0116
PREAI